Mostrar el registro sencillo del ítem

Triple combination of insulin glargine, sitagliptin and metformin in type 2 diabetes : the EASIE post-hoc analysis and extension trial

dc.contributorPontificia Universidad Javeriana. Facultad de Medicina. Departamento de Endocrinología
dc.creatorChan, Juliana C.N.
dc.creatorAschner Montoya, Pablo
dc.creatorOwens, David R.
dc.creatorPicard, Sylvie
dc.creatorVincent, Maya
dc.creatorDain, Marie Paule
dc.creatorPilorget, Valerie
dc.creatorLoizeau, Virginie
dc.creatorEchtay, Akram
dc.creatorFonseca, Vivian
dc.date2021-02-18T02:51:26Z
dc.date2021-02-18T02:51:26Z
dc.date2015
dc.date.accessioned2025-10-30T14:03:53Z
dc.date.available2025-10-30T14:03:53Z
dc.identifierhttps://www.sciencedirect.com/science/article/pii/S1056872714002530#!
dc.identifier1056-8727 / 1873-460X (Electrónico)
dc.identifierhttp://hdl.handle.net/10554/53013
dc.identifierhttps://doi.org/10.1016/j.jdiacomp.2014.08.007
dc.identifierinstname:Pontificia Universidad Javeriana
dc.identifierreponame:Repositorio Institucional - Pontificia Universidad Javeriana
dc.identifierrepourl:https://repository.javeriana.edu.co
dc.identifier.urihttp://test.repositoriodigital.com:8080/handle/123456789/193300
dc.descriptionQ3
dc.descriptionQ1
dc.descriptionAim We examined the effects of adding glargine to metformin–sitagliptin (MS + G) or sitagliptin to metformin–glargine (MG + S) therapy in type 2 diabetic persons uncontrolled after 24-week MS or MG dual therapy. Methods Subjects with A1c ≥ 7% on MS or MG treatment were respectively given glargine (0.2 U/kg starting dose) or sitagliptin (100 mg daily) for 12 weeks. The primary endpoint was number of subjects attaining A1c goal defined as < 7%. Results After receiving 24-week MS or MG dual therapy in the original EASIE Study, 42% (104/248) on MS and 68% (152/224) on MG attained A1c < 7% (p < 0.0001). The reduction in A1c was negatively associated with baseline fasting blood glucose (FBG) only in the MG group. Reduction in A1c was not related to baseline postprandial blood glucose (PPBG) in either the MG or MS group. Amongst 194 eligible patients, 57.7% (n = 111) entered the 12-week extension trial [MS + G:74/131, 57.3%; MG + S:37/63, 58.7%) with 55 (51.9%) subjects attaining goal [MS + G:59.2%; MG + S:37.1%] at week 12. The final insulin dosage was similar in both groups [MS + G: 0.46 U/kg; MG + S: 0.45 U/kg] with a higher rate of hypoglycemia in the MG + S (6.5 events/patient-year) than the MS + G group (3.2 events/patient-year), although neither group had severe hypoglycemia. Conclusion In metformin-treated type 2 diabetes patients, high fasting BG predicted greater A1c reductions with the addition of glargine, but not with sitagliptin. In subjects uncontrolled with 6-month dual therapy of MS or MG, 50% attained A1c < 7% with triple therapy of MS + G or MG + S in 12 weeks. The increased rate of hypoglycemia with MG + S (but not with MS + G) underlines the need to take measures to avoid the hypoglycemia.
dc.formatPDF
dc.formatapplication/pdf
dc.formatapplication/pdf
dc.languageeng
dc.relation134
dc.relation141
dc.relationJournal of Diabetes and Its Complications
dc.relation29
dc.relation1
dc.rightsAtribución-NoComercial 4.0 Internacional
dc.rightshttp://creativecommons.org/licenses/by-nc/4.0/
dc.rightshttp://purl.org/coar/access_right/c_abf2
dc.subjectEASIE
dc.subjectA1c
dc.subjectInsulin glargine
dc.subjectMetformin
dc.subjectSitagliptin
dc.subjectType 2 diabetes
dc.titleTriple combination of insulin glargine, sitagliptin and metformin in type 2 diabetes : the EASIE post-hoc analysis and extension trial
dc.typehttp://purl.org/coar/version/c_ab4af688f83e57aa
dc.typeArtículo de revista
dc.typehttp://purl.org/coar/resource_type/c_6501


Ficheros en el ítem

FicherosTamañoFormatoVer

No hay ficheros asociados a este ítem.
Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem